Clinical efficacy and safety of adjuvant EGFR‐TKIs for resected stage IB lung adenocarcinoma: A real‐world study based on propensity score matching

BACKGROUND: Adjuvant therapy for stage IB non‐small cell lung cancer remains debatable. In this real‐world study, we evaluate the efficacy and safety of adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) for resected stage IB lung adenocarcinoma. METHODS: This real‐worl...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Leilei, Guo, Juntang, Zhang, Weidong, Zhang, Lianbin, Liu, Xi, Wang, Tao, Zhang, Tao, Liang, Chaoyang, Liu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557892/
https://www.ncbi.nlm.nih.gov/pubmed/37559419
http://dx.doi.org/10.1002/cam4.6443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557892/
https://www.ncbi.nlm.nih.gov/pubmed/37559419
http://dx.doi.org/10.1002/cam4.6443

Ejemplares similares